TY - JOUR
T1 - Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension
AU - Geroldi, Diego
AU - Falcone, Colomba
AU - Emanuele, Enzo
AU - D'Angelo, Angela
AU - Calcagnino, Margherita
AU - Buzzi, Maria P.
AU - Scioli, Giuseppe A.
AU - Fogari, Roberto
PY - 2005/9
Y1 - 2005/9
N2 - Objectives: Advanced glycation end-products (AGE) may cause vascular stiffening by forming crosslinks through the collagen molecule or by interaction with their cellular transductional receptor (RAGE). A secreted isoform of RAGE, termed soluble RAGE (sRAGE), may contribute to the removal/detoxification of AGE by acting as a decoy. Here we studied the plasma sRAGE levels in hypertensive and normotensive human subjects. We also investigated the relationship between blood pressure parameters and plasma sRAGE concentrations. Design: A cross-sectional case-control study. Setting and participants The outpatient clinic of a university teaching hospital. Participants were 147 never-treated patients with essential hypertension (87 men and 60 women, aged 50 ± 10 years) and 177 normotensive controls (118 men and 59 women, aged 49 ± 10 years). Main outcome measures: Plasma sRAGE levels determined by enzyme-linked immunosorbent assay, systolic blood pressure (SBP), diastolic blood pressure, pulse pressure (PP) and mean arterial pressure. Results: The plasma concentration of sRAGE [median (interquartile range)] was 1206 (879-1658) pg/ml in hypertensive subjects and 1359 (999-2198) pg/ml in normotensive controls (P = 0.002). Simple correlation analysis revealed that log-transformed sRAGE levels were inversely correlated with SBP (r = -0.11; P <0.001) and PP (r = -0.23; P <0.001). Forward-selection multiple regression analysis revealed that log-transformed sRAGE levels were determined more strongly by PP (F = 3.127, P <0.001). Conclusions: Plasma sRAGE levels are decreased in patients with essential hypertension and are inversely related to PP. Our results raise the possibility that sRAGE may play a role in arterial stiffening and its complications.
AB - Objectives: Advanced glycation end-products (AGE) may cause vascular stiffening by forming crosslinks through the collagen molecule or by interaction with their cellular transductional receptor (RAGE). A secreted isoform of RAGE, termed soluble RAGE (sRAGE), may contribute to the removal/detoxification of AGE by acting as a decoy. Here we studied the plasma sRAGE levels in hypertensive and normotensive human subjects. We also investigated the relationship between blood pressure parameters and plasma sRAGE concentrations. Design: A cross-sectional case-control study. Setting and participants The outpatient clinic of a university teaching hospital. Participants were 147 never-treated patients with essential hypertension (87 men and 60 women, aged 50 ± 10 years) and 177 normotensive controls (118 men and 59 women, aged 49 ± 10 years). Main outcome measures: Plasma sRAGE levels determined by enzyme-linked immunosorbent assay, systolic blood pressure (SBP), diastolic blood pressure, pulse pressure (PP) and mean arterial pressure. Results: The plasma concentration of sRAGE [median (interquartile range)] was 1206 (879-1658) pg/ml in hypertensive subjects and 1359 (999-2198) pg/ml in normotensive controls (P = 0.002). Simple correlation analysis revealed that log-transformed sRAGE levels were inversely correlated with SBP (r = -0.11; P <0.001) and PP (r = -0.23; P <0.001). Forward-selection multiple regression analysis revealed that log-transformed sRAGE levels were determined more strongly by PP (F = 3.127, P <0.001). Conclusions: Plasma sRAGE levels are decreased in patients with essential hypertension and are inversely related to PP. Our results raise the possibility that sRAGE may play a role in arterial stiffening and its complications.
KW - Arterial stiffening
KW - Enzyme-linked immunosorbent assay
KW - Hypertension
KW - Pulse pressure
KW - Soluble receptor for advanced glycation and products
UR - http://www.scopus.com/inward/record.url?scp=24144445082&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=24144445082&partnerID=8YFLogxK
M3 - Article
C2 - 16093918
AN - SCOPUS:24144445082
VL - 23
SP - 1725
EP - 1729
JO - Journal of Hypertension
JF - Journal of Hypertension
SN - 0263-6352
IS - 9
ER -